Multiple Sclerosis stem cell therapy — your questions answered (2026)

About stem cell therapy for Multiple Sclerosis

Multiple sclerosis is an immune-mediated central-nervous-system disorder that damages myelin, axons and neurons. Autologous haematopoietic stem-cell transplantation (AHSCT) aims to rebuild the immune system after conditioning; it is fundamentally different from an MSC infusion marketed as neural repair. Neither approach should be described as replacing lost brain tissue or universally reversing disability.

The evidence for Multiple Sclerosis

AHSCT has been studied for selected people with highly active inflammatory MS, while its risks include those of intensive conditioning and immune suppression. NIH describes AHSCT as an experimental approach being compared with best available biologic therapy in severe relapsing MS. MSC, neural-cell and exosome proposals have different and generally earlier evidence. See the NINDS MS research overview and verify the exact protocol.

Do not compare a commercial infusion quote with AHSCT or disease-modifying therapy as if they were the same intervention. Itemise conditioning, hospital care, product, monitoring, infection prevention, travel, follow-up and complication responsibility, and obtain an independent MS specialist's review.

Is stem cell therapy effective for MS?

Cell therapy for Multiple Sclerosis may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

RRMS vs progressive MS?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

HSCT vs MSC — difference?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

What is the EU cost?

The partner-published indicative range for an Multiple Sclerosis programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Multiple Sclerosis (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗
• Clinic perspective — Stem Plus on Multiple Sclerosis ↗

← Back to Multiple Sclerosis overview · Multiple Sclerosis cost →